51. Scleroderma
466 clinical trials,   536 drugs   (DrugBank: 142 drugs),   110 drug target genes,   210 drug target pathways

Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
22 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03053739
(ClinicalTrials.gov)
December 201629/12/2016To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic SclerosisRandomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic SclerosisAssociated Pulmonary Arterial HypertensionDrug: Sildenafil 20mg and Bosentan 62.5mg;Drug: Sildenafil 20mg and PlaceboPostgraduate Institute of Medical Education and ResearchNULLRecruiting18 YearsN/AAll50Phase 4India
2NCT02798055
(ClinicalTrials.gov)
September 30, 20163/6/2016Bosentan Treatment of Digital Ulcers Related to Systemic SclerosisA National, Observational, Multi-center Registry to Examine the Characteristics of Patients With Systematic Sclerosis Digital Ulcers and Assess Bosentan Treatment.Systematic Sclerosis;Digital Ulcer;SclerodermaDrug: Bosentan groupElpen Pharmaceutical Co. Inc.NULLCompleted18 Years80 YearsAll148Greece
3EUCTR2014-002796-28-NL
(EUCTR)
12/04/201623/04/2015Does therapy with bosentan tablets have positive effects on the stiffness of the vessels in patients with scleroderma who have ulcers of the fingers of toes?The Clinical Efficacy And Subclinical Effects on arterial STIFFNESS of bosentan therapy added to usual care in patients with systemic sclerosis with digital ulcers. - CEASE STIFFNESS Systemic sclerosis (SSc) is characterized by skin fibrosis and visceral disease, mainly of the lungs, kidneys and the heart, accompanied by microvascular damage ultimately leading to digital ischemia. Digital ischaemia, digital ulceration (DU) or amputation are well-known manifestations of SSc. Still over 50% of the SSc patients suffer from DU. Despite effort and treatment modalities that have emerged, DU remain an important complication in SSc, even in those with mild disease.;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Trade Name: Tracleer
INN or Proposed INN: bosentan
Other descriptive name: BOSENTAN MONOHYDRATE
University Medical Center Groningen (UMCG)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
4NCT02480335
(ClinicalTrials.gov)
June 26, 201515/6/2015The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic SclerosisThe Clinical Efficacy And Subclinical Effects on Arterial STIFFNESS of Bosentan Therapy Added to Usual Care in Patients With Systemic Sclerosis With Digital UlcersScleroderma, SystemicDrug: bosentanUniversity Medical Center GroningenActelionCompleted18 YearsN/AAll20Phase 4Netherlands
5JPRN-JapicCTI-132176
01/6/2013Bosentan DUA prospective, multicenter, single arm, open-label, phase III study to assess the safety and efficacy of bosentan in patients with digital ulcers associated with systemic sclerosis (SSc) Digital ulcers associated with systemic sclerosisIntervention name : Ro47-0203 / ACT-050088
INN of the intervention : Bosentan
Dosage And administration of the intervention : Total Daily dose should be 125 mg and bosentan tablet 62.5 mg should be given twice daily (b.i.d.) after meal in the morning and evening for the first four weeks. If tolerable, the daily dosage can be increased up to 250 mg (125 mg b.i.d) from Week 5.
Control intervention name : null
Actelion Pharmaceuticals Japan Ltd.NULL18BOTH20Phase 3NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2011-005303-32-NL
(EUCTR)
05/03/201226/01/2012The effect of bosentan in scleroderma patients with a specific nailfold pattern (HOME II)Effects of bosentan in a HOMogenEous population of SSc subjects with an early or active SSc nailfold capillaroscopic pattern (HOME II) - HOME II Digital Ulcera in Systemic Sclerodermia patients
MedDRA version: 14.1;Level: PT;Classification code 10053400;Term: Endothelin increased;System Organ Class: 10022891 - Investigations;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Tracleer
INN or Proposed INN: Bosentan
Actelion Pharmaceuticals Nederland bvNULLNot RecruitingFemale: yes
Male: yes
Netherlands
7NCT01395732
(ClinicalTrials.gov)
March 20116/7/2011Bosentan in Systemic SclerosisEffects of Bosentan in a Homogenous Population of Systemic Sclerosis Subjects With a Predefined Restriction of Blood Flow in the HandsSystemic Sclerosis;Digital UlcersDrug: BosentanActelionNULLCompleted18 YearsN/ABoth18Phase 4Netherlands
8NCT01241383
(ClinicalTrials.gov)
December 201012/11/2010Effect of Bosentan in Scleroderma Renal CrisisEffect of Bosentan in the Course of Scleroderma Renal CrisisScleroderma Renal CrisisDrug: BosentanAssistance Publique - Hôpitaux de ParisActelionCompleted18 YearsN/ABoth16Phase 2France
9EUCTR2010-021452-26-FR
(EUCTR)
20/09/201009/07/2010Crise Rénale sclérodermique : amélioration du pronostic par adjonction de Bosentan au traitement de référence de la maladie - SCSREINBOCrise Rénale sclérodermique : amélioration du pronostic par adjonction de Bosentan au traitement de référence de la maladie - SCSREINBO Les patients inclus dans l'étude seront des patients atteints de sclérodermie systémique (définie selon les critères de la classification de l'ACR et/ou de Leroy et Medsger) et présentant une crise rénale sclérodermique aigue définie par une HTA sévère d'emblée et/ou d'aggravation progressive >150/85mmHg obtenue à deux reprises minimum en 24H, sans autre explication que la ScS et/ou une insuffisance rénale rapidement progressive, sans autre explication que la ScS.
MedDRA version: 8.1;Level: PT;Classification code 10062553;Term: scleroderma renal crisis
Trade Name: Tracleer
Product Name: Tracleer
INN or Proposed INN: bosentan
Trade Name: Tracleer
Product Name: Tracleer
INN or Proposed INN: Bosentan
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot RecruitingFemale: yes
Male: yes
Phase 3France
10NCT00909337
(ClinicalTrials.gov)
January 200827/5/2009Early Therapy of Pulmonary Arterial HypertensionEarly Therapy of Pulmonary Arterial HypertensionPulmonary Hypertension;Systemic SclerosisDrug: BosentanMedical University of GrazActelionCompleted18 Years90 YearsBoth10N/AAustria
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00377455
(ClinicalTrials.gov)
September 200614/9/2006Placebo Controlled Trial of Bosentan in Scleroderma PatientsPlacebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary HypertensionSystemic Scleroderma;Pulmonary HypertensionDrug: Bosentan;Drug: PlaceboGeorgetown UniversityActelionTerminated18 YearsN/AAll5Phase 2United States
12NCT00318175
(ClinicalTrials.gov)
June 200624/4/2006Effect of Bosentan on Skin Fibrosis in Patients With Systemic SclerosisStudy to Assess the Effect of Bosentan on the Treatment of Skin Fibrosis in Patients With Systemic Sclerosis (BTSF)Systemic Scleroderma;Skin Fibrosis;Hand FunctionalityDrug: Bosentan (Tracleer)Heinrich-Heine University, DuesseldorfNULLCompleted18 YearsN/ABoth10Phase 2Germany
13EUCTR2005-000701-61-GB
(EUCTR)
29/11/200527/10/2005An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis - BIRD-1An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis - BIRD-1 Scleroderma renal crisisUniversity College LondonNULLNot Recruiting Female: yes
Male: yes
15Phase 2United Kingdom
14EUCTR2004-000632-82-IT
(EUCTR)
06/04/200515/03/2007Long term open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic digital ulcersLong term open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic digital ulcers Healing and prevention of ischemic digital ulcers in patients with systemic sclerosis
Level: PTClassification code 10059084
Trade Name: TRACLEER*56CPR RIV 125MG
INN or Proposed INN: Bosentan
ACTELION PHARMACEUTICALS ITALIANULLNot RecruitingFemale: yes
Male: yes
180Italy
15NCT00226889
(ClinicalTrials.gov)
January 200523/9/2005Treatment of Early Systemic Sclerosis by BosentanSystemic Sclerosis (Scleroderma)Drug: bosentanRikshospitalet University HospitalNULLTerminated18 Years70 YearsBoth30Phase 1;Phase 2Norway
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2004-000632-82-GB
(EUCTR)
16/09/200411/02/2005Long term bosentan open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic digital ulcers - RAPIDS-2 Open label extensionLong term bosentan open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic digital ulcers - RAPIDS-2 Open label extension SSc is a multi-system disorder of unknown etiology characterized by fibrosis and vascular obliteration in the skin and visceral organs. The pathogenesis of SSc involves immunologic mechanisms vascular damage and excessive accumulation of fibrosis in the skin and internal organs. As vascular damage progresses the microvascular bed in the skin and other sites is impaired, producing a state of chronic ischemia. SSc is commonly divided into the diffuse and limited form of the diseaseTrade Name: Tracleer
Product Name: bosentan
Product Code: Ro 47-0203
INN or Proposed INN: bosentan monohydrate
Actelion Pharmaceuticals Ltd.NULLNot RecruitingFemale: yes
Male: yes
180Phase 3Italy;United Kingdom
17EUCTR2004-000631-28-IT
(EUCTR)
14/09/200417/09/2004Bosentan use in interstitial lung disease (open label). Long-term open-label study in patients with interstitial lung disease associated with systemic sclerosis who completed the protocol AC-052-330/BUILD 2.Bosentan use in interstitial lung disease (open label). Long-term open-label study in patients with interstitial lung disease associated with systemic sclerosis who completed the protocol AC-052-330/BUILD 2. Interstitial lung disease associated with systemic sclerosisTrade Name: TRACLEER*125MG 56CPR RIV.
Product Name: NA
Product Code: NA
INN or Proposed INN: Bosentan
ACTELION PHARMACEUTICALS ITALIANULLNot RecruitingFemale: yes
Male: yes
Italy
18NCT00319696
(ClinicalTrials.gov)
July 8, 200427/4/2006Bosentan in Digital UlcersLong-term Bosentan Open Label Extension of the AC-052-331 Study in Systemic Sclerosis Patients With Ischemic Digital UlcersDigital UlcersDrug: Bosentan 62.5 mg;Drug: Bosentan 125 mgActelionNULLCompleted18 YearsN/AAll116Phase 3United States;Austria;Canada;France;Germany;Italy;Switzerland;United Kingdom
19NCT00319033
(ClinicalTrials.gov)
July 200426/4/2006Open-label Study With Bosentan in Interstitial Lung DiseaseLong-term Open-label Study in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis Who Completed the Protocol AC-052-330.Interstitial Lung Disease;SclerodermaDrug: bosentanActelionNULLCompleted18 YearsN/ABoth132Phase 2;Phase 3United States;Canada;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Sweden;Switzerland;United Kingdom
20NCT02800993
(ClinicalTrials.gov)
October 200313/6/2016Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With SclerodermaA Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic SclerosisSystemic Sclerosis;Digital UlcersDrug: Bosentan 62.5 mg;Drug: Bosentan 125 mg;Drug: PlaceboActelionNULLCompleted18 YearsN/ABoth188Phase 3United States;Canada
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT00077584
(ClinicalTrials.gov)
October 200310/2/2004Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With SclerodermaA Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic SclerosisDigital Ulcers;Systemic SclerosisDrug: Bosentan 62.5 mg;Drug: Bosentan 125 mg;Drug: PlaceboActelionNULLCompleted18 YearsN/ABoth188Phase 3United States;Canada
22NCT00070590
(ClinicalTrials.gov)
July 20036/10/2003Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With SclerodermaA Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic SclerosisPulmonary Fibrosis;Scleroderma, SystemicDrug: BosentanActelionNULLCompleted18 YearsN/ABoth132Phase 2;Phase 3United States;France;Germany;Israel;Italy;Netherlands;Sweden;Switzerland;United Kingdom